June 18, 2026 17:00 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website. Q2 2026 Aide Memoire Teva has compiled this document with public information
June 18, 2026 16:57 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric
June 18, 2026 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following
June 18, 2026 09:03 ET | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., June 18, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL), a non-profit, biotech focused on completing development and enabling access to stalled rare disease treatments, to support the advancement of novel therapeutic programs. The strategic partnership is built on
June 18, 2026 07:45 ET | Source: Curium BOSTON, June 18, 2026 (GLOBE NEWSWIRE) — Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium™ concerning Curium’s Lutetium Lu 177 dotatate product. In the court decision issued yesterday by the Delaware U.S. District Court, Justice
June 18, 2026 04:05 ET | Source: Boehringer Ingelheim Limited Not intended for UK and US audiences Ingelheim, Germany – Long-term survival modeling of Boehringer Ingelheim’s oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive
June 16, 2026 08:30 ET | Source: Optimi Health Corp. Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi’s psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country’s Authorized Prescriber Scheme
June 15, 2026 11:04 ET | Source: BLUMM KNOWHOW S.R.L A great celebration of sport and community, with d’Annunzio University’s “sea of blue” among the most visible features of the 26th edition of the Chieti Night Run. The University of Chieti-Pescara took part with 262 entrants, including students and staff, bringing a strong message of wellbeing, community
June 14, 2026 18:05 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating
Leading allergy experts to convene in Istanbul to explore how science, prevention and policy can reduce the global impact of allergic diseases June 12, 2026 01:00 ET | Source: European Academy of Allergy and Clinical Immunology ZURICH, June 12, 2026 (GLOBE NEWSWIRE) — As allergic diseases continue to affect hundreds of millions of people worldwide and place
June 11, 2026 04:36 ET | Source: Global Liver Institute Washington, D.C., June 11, 2026 (GLOBE NEWSWIRE) — Global Fatty Liver Day 2026 comes at a pivotal moment for liver health worldwide. Following the adoption of the landmark World Health Organization (WHO) Resolution on Reducing the Burden of Noncommunicable Diseases, communities around the world are increasingly recognizing steatotic liver disease (SLD)
June 11, 2026 03:04 ET | Source: Curium BOSTON, June 11, 2026 (GLOBE NEWSWIRE) — Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan. 64Cu-PSMA-I&T is a PET radiopharmaceutical targeting PSMA. 64Cu-PSMA-I&T is being assessed as a PET agent labeled
June 10, 2026 12:03 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. “This acquisition reflects our Pivot to
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation June 10, 2026 08:00 ET | Source: Kyowa Kirin PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further
The partnership brings Nucleus’ advanced carrier and embryo screening to Hawaii’s largest IVF practice June 09, 2026 09:00 ET | Source: Nucleus Genomics Inc. NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics today announced an IVF+ partnership with the Fertility Institute of Hawaii, bringing its advanced carrier screening and embryo analysis to Hawaii’s largest IVF practice. Through the collaboration, patients
